DE69923559T2 - Methoden zur inhibierung von helicobacter pylori - Google Patents
Methoden zur inhibierung von helicobacter pylori Download PDFInfo
- Publication number
- DE69923559T2 DE69923559T2 DE69923559T DE69923559T DE69923559T2 DE 69923559 T2 DE69923559 T2 DE 69923559T2 DE 69923559 T DE69923559 T DE 69923559T DE 69923559 T DE69923559 T DE 69923559T DE 69923559 T2 DE69923559 T2 DE 69923559T2
- Authority
- DE
- Germany
- Prior art keywords
- urei
- helicobacter
- pylori
- strain
- urease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000590002 Helicobacter pylori Species 0.000 title claims abstract description 21
- 229940037467 helicobacter pylori Drugs 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 title claims abstract description 19
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 13
- 230000000694 effects Effects 0.000 claims abstract description 36
- 238000001727 in vivo Methods 0.000 claims abstract description 15
- 230000004083 survival effect Effects 0.000 claims abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 65
- 101150055940 ureI gene Proteins 0.000 claims description 48
- 239000013612 plasmid Substances 0.000 claims description 21
- 241000589989 Helicobacter Species 0.000 claims description 20
- 230000002950 deficient Effects 0.000 claims description 19
- 238000000338 in vitro Methods 0.000 claims description 9
- 238000012360 testing method Methods 0.000 claims description 8
- 108020004705 Codon Proteins 0.000 claims description 7
- 230000012010 growth Effects 0.000 claims description 7
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 7
- 238000012217 deletion Methods 0.000 claims description 6
- 230000037430 deletion Effects 0.000 claims description 6
- 229930027917 kanamycin Natural products 0.000 claims description 6
- 229960000318 kanamycin Drugs 0.000 claims description 6
- 229930182823 kanamycin A Natural products 0.000 claims description 6
- 241000590017 Helicobacter felis Species 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 230000035945 sensitivity Effects 0.000 claims description 4
- 241000590006 Helicobacter mustelae Species 0.000 claims description 3
- 108700007698 Genetic Terminator Regions Proteins 0.000 claims description 2
- 241001503513 Helicobacter bilis Species 0.000 claims description 2
- 241001148144 Helicobacter canis Species 0.000 claims description 2
- 241001495142 Helicobacter heilmannii Species 0.000 claims description 2
- 241001453258 Helicobacter hepaticus Species 0.000 claims description 2
- 241000590012 Helicobacter muridarum Species 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 10
- 238000012216 screening Methods 0.000 abstract description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 66
- 108010046334 Urease Proteins 0.000 description 64
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 39
- 102000004169 proteins and genes Human genes 0.000 description 36
- 239000004202 carbamide Substances 0.000 description 26
- 241000894006 Bacteria Species 0.000 description 19
- 229910021529 ammonia Inorganic materials 0.000 description 19
- 230000002378 acidificating effect Effects 0.000 description 14
- 101100427860 Brucella suis biovar 1 (strain 1330) ureE1 gene Proteins 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- 101150008224 ureE gene Proteins 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 10
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 238000011534 incubation Methods 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 101710196855 Aliphatic amidase Proteins 0.000 description 6
- 230000032258 transport Effects 0.000 description 6
- 108010052285 Membrane Proteins Proteins 0.000 description 5
- 102000018697 Membrane Proteins Human genes 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 229910052759 nickel Inorganic materials 0.000 description 5
- 101150109657 ureF gene Proteins 0.000 description 5
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- 108700023418 Amidases Proteins 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- 206010019375 Helicobacter infections Diseases 0.000 description 4
- 229960005091 chloramphenicol Drugs 0.000 description 4
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 108091008053 gene clusters Proteins 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 241000186840 Lactobacillus fermentum Species 0.000 description 3
- 241000187480 Mycobacterium smegmatis Species 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 241000187562 Rhodococcus sp. Species 0.000 description 3
- 102000005922 amidase Human genes 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000030570 cellular localization Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 229940012969 lactobacillus fermentum Drugs 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000013605 shuttle vector Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588915 Klebsiella aerogenes Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 241000607762 Shigella flexneri Species 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 241000194024 Streptococcus salivarius Species 0.000 description 2
- 241000607447 Yersinia enterocolitica Species 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- RRUDCFGSUDOHDG-UHFFFAOYSA-N acetohydroxamic acid Chemical compound CC(O)=NO RRUDCFGSUDOHDG-UHFFFAOYSA-N 0.000 description 2
- 229960001171 acetohydroxamic acid Drugs 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000006161 blood agar Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- UXZFGBLZXMQRFR-UHFFFAOYSA-N methylurea thiourea Chemical compound CNC(=O)N.NC(=S)N UXZFGBLZXMQRFR-UHFFFAOYSA-N 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000004902 response to acidity Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 229940098232 yersinia enterocolitica Drugs 0.000 description 2
- 108091006112 ATPases Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 101100301559 Bacillus anthracis repS gene Proteins 0.000 description 1
- 101100247969 Clostridium saccharobutylicum regA gene Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 101100412434 Escherichia coli (strain K12) repB gene Proteins 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 241001473944 Helicobacter pylori N6 Species 0.000 description 1
- 241001473947 Helicobacter pylori SS1 Species 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 101100049353 Hypocrea virens (strain Gv29-8 / FGSC 10586) virC gene Proteins 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-O Methylammonium ion Chemical compound [NH3+]C BAVYZALUXZFZLV-UHFFFAOYSA-O 0.000 description 1
- QWZFVMCWPLMLTL-UHFFFAOYSA-N N-diaminophosphoryl-4-fluorobenzamide Chemical compound NP(N)(=O)NC(=O)C1=CC=C(F)C=C1 QWZFVMCWPLMLTL-UHFFFAOYSA-N 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241001495084 Phylo Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 101710090029 Replication-associated protein A Proteins 0.000 description 1
- 241001290479 Rhodococcus sp. R312 Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 101100114425 Streptococcus agalactiae copG gene Proteins 0.000 description 1
- 101100053618 Yersinia enterocolitica yscE gene Proteins 0.000 description 1
- 108010048241 acetamidase Proteins 0.000 description 1
- 150000008431 aliphatic amides Chemical class 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 101150055766 cat gene Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229950007143 flurofamide Drugs 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 238000003167 genetic complementation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- -1 lso Species 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 229940080818 propionamide Drugs 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 101150044854 repA gene Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 101150030895 ureAB gene Proteins 0.000 description 1
- 101150061086 ureB gene Proteins 0.000 description 1
- 101150070667 ureD gene Proteins 0.000 description 1
- 101150046666 ureG gene Proteins 0.000 description 1
- 101150118265 ureH gene Proteins 0.000 description 1
- 230000004143 urea cycle Effects 0.000 description 1
- 108020003234 urea transporter Proteins 0.000 description 1
- 102000006030 urea transporter Human genes 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 239000002601 urease inhibitor Substances 0.000 description 1
- 230000003604 ureolytic effect Effects 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/58—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving urea or urease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/121—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Helicobacter (Campylobacter) (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/205—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Campylobacter (G)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US107383 | 1993-08-16 | ||
| US09/107,383 US6190667B1 (en) | 1998-06-30 | 1998-06-30 | Methods of inhibiting Helicobacter pylori |
| PCT/EP1999/004490 WO2000000634A2 (en) | 1998-06-30 | 1999-06-29 | METHODS OF INHIBITING $i(HELICOBACTER PYLORI) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69923559D1 DE69923559D1 (de) | 2005-03-10 |
| DE69923559T2 true DE69923559T2 (de) | 2006-02-16 |
Family
ID=22316366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69923559T Expired - Lifetime DE69923559T2 (de) | 1998-06-30 | 1999-06-29 | Methoden zur inhibierung von helicobacter pylori |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US6190667B1 (enExample) |
| EP (1) | EP1092040B1 (enExample) |
| JP (1) | JP4445128B2 (enExample) |
| AT (1) | ATE288498T1 (enExample) |
| AU (1) | AU4779599A (enExample) |
| DE (1) | DE69923559T2 (enExample) |
| ES (1) | ES2237119T3 (enExample) |
| PT (1) | PT1092040E (enExample) |
| WO (1) | WO2000000634A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6190667B1 (en) * | 1998-06-30 | 2001-02-20 | Institut Pasteur | Methods of inhibiting Helicobacter pylori |
| US5942409A (en) * | 1998-07-31 | 1999-08-24 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Process for identification of substances modulating ureI dependent mechanisms of Helicobacter pylori metabolism |
| US20030113742A1 (en) * | 2001-04-20 | 2003-06-19 | University Of Iowa Research Foundation | Methods and compositions for the modulation of biofilm formation |
| US20070092502A1 (en) * | 2005-09-01 | 2007-04-26 | Allergan, Inc. | Method of Treating Glaucoma |
| ATE465928T1 (de) | 2005-11-21 | 2010-05-15 | Faroex Ltd | Verbundkarosserie für ein fahrzeug |
| CA2599560C (en) | 2006-09-01 | 2011-04-12 | Faroex Ltd. | Structural shear plate for a vehicle |
| DK2270133T3 (en) | 2008-04-22 | 2015-09-07 | Corporación Alimentaria Peñasanta Capsa | Method of obtaining a new strain of Bifidobacterium bidifum with effect against infection with Helicobacter pylori |
| CN111471780A (zh) * | 2020-03-16 | 2020-07-31 | 上海力拜生物科技有限公司 | 幽门螺杆菌唾液检测生物标志物及其应用 |
| CN117050169B (zh) * | 2023-08-14 | 2024-04-26 | 苏州东抗生物科技有限公司 | 一种针对UreA蛋白的单克隆抗体及其应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USH25H (en) | 1985-06-17 | 1986-02-04 | Tennessee Valley Authority | Thiophosphoryl triamide as a urease inhibitor |
| FR2637612B1 (fr) | 1988-10-06 | 1993-09-10 | Pasteur Institut | Sequences de nucleotides codant pour une proteine a activite ureasique |
| GB8928625D0 (en) | 1989-12-19 | 1990-02-21 | 3I Res Expl Ltd | H.pylori dna probes |
| JPH04364160A (ja) | 1990-08-03 | 1992-12-16 | Terumo Corp | チオウレア誘導体およびこれを含有する抗菌剤および抗潰瘍剤 |
| JPH0559038A (ja) | 1991-09-06 | 1993-03-09 | Terumo Corp | チオウレア誘導体及びこれを含有する医薬製剤 |
| FR2682122B1 (fr) * | 1991-10-03 | 1995-06-09 | Pasteur Institut | Nouveaux genes d'helicobacter pylori. leur utilisation pour la preparation de souches recombinantes de h. pylori. |
| US5409903A (en) | 1992-02-18 | 1995-04-25 | Urecap Corporation | Method and compositions for the treatment of H. pylori and dermatitis |
| US5472695A (en) * | 1992-06-25 | 1995-12-05 | Technion Research And Development Foundation Ltd. | Therapeutic application of a thyme extract and in - vitro methods for inhibiting the growth and urease activity of helicobacter pylori |
| MX9304638A (es) | 1992-07-31 | 1994-05-31 | Neose Pharm Inc | Composicion para tratar e inhibir las ulceras gastricas y duodenales. |
| US5972336A (en) * | 1992-11-03 | 1999-10-26 | Oravax Merieux Co. | Urease-based vaccine against helicobacter infection |
| US6258359B1 (en) * | 1993-05-19 | 2001-07-10 | Institut Pasteur | Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides |
| JPH08509873A (ja) * | 1993-05-19 | 1996-10-22 | アンスティテュ・パストゥール | ヘリコバクター感染に対する免疫組成物、該組成物に用いられるポリペプチドおよび該ポリペプチドをコードする核酸配列 |
| US5441875A (en) | 1993-07-23 | 1995-08-15 | Brigham And Women's Hospital | Urea transporter polypeptide |
| US5560912A (en) * | 1994-06-27 | 1996-10-01 | Technion Research & Development Foundation Ltd. | Method for inhibiting growth of helicobacter pylori |
| DE69637947D1 (de) | 1995-04-28 | 2009-07-23 | Merieux Oravax Snc | Multimerer, rekombinanter urease impfstoff |
| DE69636320T2 (de) | 1995-06-02 | 2007-07-26 | Eisai R&D Management Co., Ltd. | Helicobacter Polypeptide, deren Herstellung und Verwendung |
| SK165197A3 (en) | 1995-06-07 | 1999-01-11 | Astra Ab | Nucleic acid and amino acid sequences relating to helicobacter pylori for diagnostics and therapeutics |
| US6087358A (en) * | 1995-06-26 | 2000-07-11 | Pathogenesis Corporation | Nitro-[2,1-b]imidazopyran compounds and antibacterial uses thereof |
| FR2736360B1 (fr) * | 1995-07-04 | 1997-09-05 | Pasteur Institut | Clonage et caracterisation du gene fiba de h.pylori, production de souches aflagellees |
| TW290498B (en) * | 1995-07-19 | 1996-11-11 | Andover Coated Products Inc | Elastic bandage |
| SE506529C2 (sv) | 1996-01-23 | 1997-12-22 | Semper Ab | Användning av ett laktoperoxidassystem för framställning av ett läkemedel mot Helicobacter pylori |
| US5900410A (en) | 1996-08-27 | 1999-05-04 | Hartmann; John F. | Monotherapy of peptic ulcers and gastritis |
| EP0939800A2 (en) * | 1996-10-17 | 1999-09-08 | Institut Pasteur | HELICOBACTER ANTIGEN (gamma-GLUTAMYLTRANSFERASE) AND SEQUENCES ENCODING THE SAME |
| AU742521B2 (en) * | 1997-01-24 | 2002-01-03 | Avi Biopharma, Inc. | Method and conjugate for treating H. pylori infection |
| US5876946A (en) * | 1997-06-03 | 1999-03-02 | Pharmacopeia, Inc. | High-throughput assay |
| US5985631A (en) * | 1997-09-12 | 1999-11-16 | Oravax-Merieux Co. | Method for preventing the activation of inactive, recombinant Helicobacter pylori apourease |
| US6190667B1 (en) * | 1998-06-30 | 2001-02-20 | Institut Pasteur | Methods of inhibiting Helicobacter pylori |
| US5942409A (en) * | 1998-07-31 | 1999-08-24 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Process for identification of substances modulating ureI dependent mechanisms of Helicobacter pylori metabolism |
| ES2191470T3 (es) * | 1998-10-02 | 2003-09-01 | 3M Innovative Properties Co | Material compuesto, elastico y estratificado. |
| US20040142343A1 (en) * | 2002-08-16 | 2004-07-22 | Yung-Fu Chang | Helicobacter bizzozeronii urease genes and their uses in diagnostic and treatment methods |
-
1998
- 1998-06-30 US US09/107,383 patent/US6190667B1/en not_active Expired - Fee Related
-
1999
- 1999-06-29 EP EP99931212A patent/EP1092040B1/en not_active Expired - Lifetime
- 1999-06-29 PT PT99931212T patent/PT1092040E/pt unknown
- 1999-06-29 AU AU47795/99A patent/AU4779599A/en not_active Abandoned
- 1999-06-29 JP JP2000557387A patent/JP4445128B2/ja not_active Expired - Fee Related
- 1999-06-29 AT AT99931212T patent/ATE288498T1/de not_active IP Right Cessation
- 1999-06-29 ES ES99931212T patent/ES2237119T3/es not_active Expired - Lifetime
- 1999-06-29 DE DE69923559T patent/DE69923559T2/de not_active Expired - Lifetime
- 1999-06-29 WO PCT/EP1999/004490 patent/WO2000000634A2/en not_active Ceased
-
2000
- 2000-08-23 US US09/643,914 patent/US6416968B1/en not_active Expired - Fee Related
- 2000-12-22 US US09/742,361 patent/US6762051B2/en not_active Expired - Fee Related
-
2003
- 2003-11-25 US US10/720,470 patent/US20040115772A1/en not_active Abandoned
-
2005
- 2005-03-02 US US11/068,826 patent/US7517666B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002519039A (ja) | 2002-07-02 |
| AU4779599A (en) | 2000-01-17 |
| DE69923559D1 (de) | 2005-03-10 |
| US7517666B2 (en) | 2009-04-14 |
| US20040115772A1 (en) | 2004-06-17 |
| EP1092040A2 (en) | 2001-04-18 |
| WO2000000634A2 (en) | 2000-01-06 |
| JP4445128B2 (ja) | 2010-04-07 |
| US20020102269A1 (en) | 2002-08-01 |
| US20050176077A1 (en) | 2005-08-11 |
| EP1092040B1 (en) | 2005-02-02 |
| WO2000000634A3 (en) | 2000-04-13 |
| ES2237119T3 (es) | 2005-07-16 |
| US6416968B1 (en) | 2002-07-09 |
| US6762051B2 (en) | 2004-07-13 |
| PT1092040E (pt) | 2005-06-30 |
| ATE288498T1 (de) | 2005-02-15 |
| US6190667B1 (en) | 2001-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Myhal et al. | Relative colonizing abilities of human fecal and K 12 strains of Escherichia coli in the large intestines of streptomycin-treated mice | |
| Lambert et al. | Susceptibility of Campylobacter pyloridis to 20 antimicrobial agents | |
| Xie et al. | Environmental regulation of fimbrial gene expression in Porphyromonas gingivalis | |
| Lacroix et al. | Salmonella typhimurium acrB-like gene: identification and role in resistance to biliary salts and detergents and in murine infection | |
| Skouloubris et al. | The Helicobacter pylori UreI protein is not involved in urease activity but is essential for bacterial survival in vivo | |
| Williams et al. | ColV plasmid-mediated, colicin V-independent iron uptake system of invasive strains of Escherichia coli | |
| Seong Kim et al. | Molecular cloning and characterization of the Helicobacter pylori fliD gene, an essential factor in flagellar structure and motility | |
| DE69233522T2 (de) | Für die regulation und reifung von urease notwendige helicobakter pylori-gene und ihre nutzung | |
| Nilius et al. | Coccoid like forms (CLF) of Helicobacter pylori. Enzyme activity and antigenicity | |
| Bârzu et al. | Functional analysis of the Shigella flexneri IpaC invasin by insertional mutagenesis | |
| Andrutis et al. | Infection of the ferret stomach by isogenic flagellar mutant strains of Helicobacter mustelae | |
| DE69533514T2 (de) | Antigenes Fragment des tagA-Gens und Methoden zum Nachweis der Prädisposition von Magengeschwür und Magenkarzinom | |
| DE69923559T2 (de) | Methoden zur inhibierung von helicobacter pylori | |
| Nagata et al. | Inhibitory action of lansoprazole and its analogs against Helicobacter pylori: inhibition of growth is not related to inhibition of urease | |
| DE69214277T2 (de) | Dna-sequenzen, die für die virulente eigenschaft von -i(streptococcus suis) kodieren, und teile davon, polypeptide und antikörper die sich davon ableiten und deren verwendung für diagnose und prophylaxe der infektion mit streptococcus suis in säugetieren, insbesondere in menschen | |
| Nicholson et al. | Application of Lior biotyping by use of genetically identified Campylobacter strains | |
| Mingrone et al. | Characteristics of Yersinia enterocolitica isolated from children with diarrhea in Italy | |
| Petrocheilou et al. | Spread of a single plasmid clone to an untreated individual from a person receiving prolonged tetracycline therapy | |
| Glupczynski | The diagnosis of Helicobacter pylori infection: a microbiologist's perspective | |
| CA2233570C (en) | Detection, prevention and treatment of papillomatous digital dermatitis | |
| Ørskov et al. | Assessment of biological and colony hybridization assays for detection of the aerobactin system in Escherichia coli from urinary tract infections | |
| Lacroix et al. | Salmonella typhimurium TnphoA mutants with increased sensitivity to biological and chemical detergents | |
| DE19521314A1 (de) | Adhärenzgen aus Helicobacter pylori und davon codiertes Polypeptid | |
| WO2001073440A2 (de) | Nachweis von diarrhogenen e.coli-keimen | |
| Miliotis et al. | Identification of a conjunctivitis-associated gene locus from the virulence plasmid of Yersinia enterocolitica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |